Doctors seek goldilocks dose for stroke drug

NCT ID NCT07047326

Recruiting now Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

Summary

This study aims to find the safest and most effective dose of a clot-dissolving drug called urokinase for people having a stroke. Researchers will test different amounts in a small group of patients to determine the maximum safe dose and create a dosing guide based on patient weight. The goal is to standardize treatment to improve recovery and reduce bleeding risks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Xuanwu Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100053, China

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE ISCHEMIC STROKE